The DMTF1 Knockout HAP1 Polyclonal Cells represent a CRISPR/Cas9-edited polyclonal knockout cell population engineered for loss-of-function studies of the DMTF1 gene. This product provides a genetically disrupted pool of HAP1 cells, enabling researchers to investigate DMTF1-dependent signaling without clonal bias. The polyclonal format allows for averaging of gene-editing outcomes across multiple alleles, making it suitable for pooled functional genomics screens and bulk molecular assays where uniform knockout efficiency is not required.
The HAP1 host cell line is a near-haploid human cell line derived from the chronic myelogenous leukemia (CML)-derived KBM-7 line. Its haploid karyotype simplifies genetic manipulation and phenotypic analysis, as a single genomic alteration can produce a complete loss-of-function phenotype. HAP1 cells are widely used in haploid genetic screens, drug response profiling, and mechanistic studies of cancer-relevant pathways, particularly those related to hematological malignancies. The CML origin endows these cells with constitutive BCR-ABL kinase activity, providing a disease-relevant background for leukemia research.
DMTF1 (cyclin D-binding Myb-like transcription factor 1) is a tumor suppressor that integrates signals from oncogenic Ras and DNA damage to regulate the ARF?Cp53 axis. Under stress conditions, DMTF1 is activated and transcriptionally upregulates ARF (CDKN2A), which sequesters MDM2, thereby stabilizing p53. Activated p53 then promotes cell cycle arrest via p21 and apoptosis via Bax. DMTF1 directly interacts with cyclin D1 and CDK4, linking cell cycle progression to tumor suppression. In this knockout model, disruption of DMTF1 disables the ARF?Cp53-mediated checkpoint, leading to enhanced proliferation and reduced apoptotic potential in response to genotoxic stress.
In the HAP1 haploid background, loss of DMTF1 unmasks the tumor-suppressive function of this transcription factor without interference from a second allele. This allows for clear dissection of DMTF1??s role in cell cycle control and apoptosis, particularly in the context of CML-driven leukemogenesis. The polyclonal knockout population can be used to study how DMTF1 deficiency cooperates with BCR-ABL signaling, potentially modeling advanced-phase CML or other cancers where DMTF1 is deregulated. It also serves as a platform for high-throughput screens to identify synthetic lethal interactions or therapeutic targets.
Typical research applications include Western blotting for p53, p21, and Bax to assess pathway activation; RT-qPCR for ARF expression; Annexin V-based apoptosis assays; cell proliferation studies; and drug sensitivity testing against p53-activating agents or CDK4 inhibitors. The polyclonal format is ideal for RNA-seq and other -omics approaches to characterize the broader transcriptional consequences of DMTF1 loss. These cells support functional genomics validation, tumor suppressor biology, and preclinical drug target assessment. For further details, please contact Ascent Research.
